Core Insights - Whales have adopted a bullish stance on uniQure, with 44% of trades reflecting bullish expectations and 40% bearish [1] - The total amount for bullish call options is $1,207,992, while bearish put options total $98,000 [1] - Whales have targeted a price range for uniQure between $5.0 and $30.0 over the last three months [2] Options Activity - A snapshot of options trading indicates significant interest in uniQure's options, particularly within the strike price range of $5.0 to $30.0 [3] - The volume and open interest data are essential for assessing liquidity and interest levels in uniQure's options [3] Company Overview - uniQure NV is a gene therapy company focused on developing treatments for genetic diseases, including hemophilia and Huntington's disease, and collaborates with Bristol Myers Squibb for cardiovascular disease therapies [4] Current Market Status - The average target price proposed by five industry analysts for uniQure is $27.6 [6] - The current trading volume for uniQure is 10,245,957, with the stock price up by 22.56% to $17.49 [7] - RSI readings suggest that the stock may be approaching overbought conditions [7]